Welcome to our dedicated page for Adamis Pharmaceuticals Corporation news (Ticker: ADMP), a resource for investors and traders seeking the latest updates and insights on Adamis Pharmaceuticals Corporation stock.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a renowned specialty biopharmaceutical company committed to developing and commercializing therapeutic solutions in critical areas such as opioid overdose, allergies, respiratory diseases, and inflammatory conditions. The company operates in two primary divisions: specialty pharmaceuticals and biotechnology.
In the specialty pharmaceutical division, Adamis has a promising pipeline that includes four pivotal products: the Epinephrine Injection Pre-Filled Syringe (PFS) for emergency treatment of anaphylaxis, APC-1000 and APC-5000 (dry powder inhalers) for asthma and COPD, and APC-3000, a Hydrofluoroalkane (HFA) inhaled nasal steroid for treating allergic rhinitis. Their strategy aims to offer cost-effective therapeutic alternatives for large market needs, ensuring affordability and accessibility. The company follows the 505(b)(2) regulatory pathway to streamline development and reduce time to market.
In the biotechnology division, Adamis focuses on innovative treatments for diseases with considerable unmet needs. This division's portfolio includes four developmental products, such as TeloB-Vax, which holds promise for treating cancer and infectious diseases. Following its recent merger with DMK Pharmaceuticals, Adamis is now advancing DPI-125, a clinical-stage therapeutic aimed at treating opioid use disorder, a significant public health crisis that requires urgent intervention.
Adamis has received FDA approval for two critical products: ZIMHI® (naloxone) Injection for opioid overdose and SYMJEPI® (epinephrine) Injection for acute allergic reactions, including anaphylaxis. These products are designed to provide rapid, life-saving interventions in emergency situations.
Financially, Adamis is navigating challenges, including maintaining Nasdaq listing compliance and achieving financial stability. Recent measures include a reverse stock split to meet Nasdaq requirements and securing additional funding through public offerings.
Adamis is actively involved in partnerships and collaborations to further its mission. The company recently participated in the White House Roundtable on Opioid Reversal Product Manufacturers and received a grant from the NIH to develop treatment for alcohol use disorder. These initiatives underline Adamis' commitment to addressing public health crises through innovative therapeutic solutions.
The management team, led by CEO Ebrahim Versi, MD, PhD, is focused on expanding the company's product portfolio and improving financial health. The recent merger with DMK Pharmaceuticals is a strategic move to enhance their capabilities in developing neuro-based treatments and leveraging DMK's extensive library of small molecule neuropeptide analogues.
Adamis Pharmaceuticals remains dedicated to making a significant impact in the biopharmaceutical landscape by developing and commercializing treatments that address critical health challenges, ensuring better outcomes for patients worldwide.
Adamis Pharmaceuticals (Nasdaq: ADMP) announced that NIH researchers identified Tempol as a potential oral treatment for COVID-19, which may stop virus replication and prevent severe disease. The FDA has authorized Adamis to initiate a clinical study of Tempol as a home treatment, aiming to reduce the healthcare burden of COVID-19. Tempol’s properties, including antioxidant and anti-inflammatory effects, could also address other viral respiratory infections. Adamis holds exclusive rights to Tempol for treating respiratory diseases, establishing a promising pathway for its future.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc., for up to $15 million over 12 months. This move aims to focus on the development of its prescription pharmaceutical pipeline. Proceeds will be used for general corporate purposes and to accelerate ongoing development efforts. Further details will be provided in a forthcoming Form 8-K report.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) reported the re-election of its Board members at the 2021 Annual Meeting of Stockholders. The nominees—Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio, and Richard C. Williams—were confirmed, along with approval for executive compensation and the appointment of BDO USA, LLP as the accounting firm for 2021. The company continues to focus on developing therapeutic products, including SYMJEPI for allergic reactions and ZIMHI for opioid overdose, currently under FDA review.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) calls on stockholders to reelect all five Board members during the Annual Meeting on July 16, 2021. The Board highlighted engagement with stockholders to incorporate their feedback into governance and operational strategies. They emphasized the momentum in the company’s pipeline and a commitment to prioritizing stockholder interests. The firm is advancing its product candidates, including SYMJEPI and ZIMHI, while focusing on addressing acute allergic reactions and opioid overdoses.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) issued a letter to stockholders urging them to re-elect all five Board members at the Annual Meeting on July 16, 2021. The Board emphasizes the importance of continuity to enhance FDA review processes for their ZIMHI New Drug Application and advance clinical trials for Tempol. They highlight recent pipeline momentum and warn against stockholder Jerald A. Hammann's attempt to replace board members, citing his lack of experience and previous litigation history. The Board believes their re-election will safeguard stockholder investments and support company growth.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has sent a letter to stockholders ahead of its Annual Meeting on July 16, urging support for the re-election of all five Board members. The Board emphasizes the importance of continuity as the company progresses with its development pipeline, particularly the Phase 2/3 trial of Tempol for COVID-19 treatment. Recent NIH studies indicate Tempol's antiviral potential, and preparations for the clinical trial are in progress. The Board also addresses litigation challenges posed by a shareholder, insisting it threatens company stability.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) filed its definitive proxy statement with the SEC and urged stockholders to vote for the re-election of its Board at the Annual Meeting on July 16, 2021. The Board emphasized its commitment to developing breakthrough drugs for allergies, respiratory diseases, and opioid overdoses, particularly during the ongoing COVID-19 pandemic. Adamis reported over 75% total stockholder returns in the past year, citing successful initiatives, including the advancement of its naloxone injection product and Tempol for COVID-19, aiming for regulatory approvals to drive long-term value.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the initiation of clinical trial start-up activities for its experimental drug, Tempol, aimed at treating COVID-19. The trial, titled NCT04729595, is a Phase 2/3, randomized, double-blind study focused on Tempol's safety and efficacy in preventing hospitalization due to COVID-19. The trial follows promising findings from the National Institutes of Health, indicating Tempol’s potential antiviral properties against SARS-CoV-2, surpassing Remdesivir in certain aspects. Adamis holds a global license for Tempol, which can also be used for other respiratory diseases.
Adamis Pharmaceuticals Corporation announced the FDA's acceptance of its resubmitted New Drug Application (NDA) for ZIMHI, a higher naloxone injection aimed at treating opioid overdose. The FDA deems the application complete and has set a target action date of November 12, 2021. This decision highlights the increasing need for effective treatment alternatives amid the rising opioid crisis, which has seen overdose deaths soar by over five times since 1999. Adamis aims to work closely with the FDA to foster ZIMHI’s approval and commercialization.
Adamis Pharmaceuticals (NASDAQ: ADMP) has announced that the National Institutes of Health (NIH) recognizes its experimental drug Tempol as a promising potential oral antiviral for COVID-19. Studies show Tempol limits SARS-CoV-2 infection by impairing the virus's RNA replicase enzyme. The NIH plans further investigations, including a clinical study on Tempol's efficacy in treating early COVID-19 infections. Previous studies demonstrated Tempol's anti-inflammatory effects, and its usage is being expanded for respiratory diseases.
FAQ
What is the market cap of Adamis Pharmaceuticals Corporation (ADMP)?
What are the main therapeutic areas Adamis Pharmaceuticals Corporation focuses on?
What products are in Adamis Pharmaceuticals' pipeline?
What recent merger has Adamis Pharmaceuticals completed?
What are Adamis' FDA-approved products?
What steps has Adamis taken to maintain its Nasdaq listing?
Who is the CEO of Adamis Pharmaceuticals?
What was the outcome of Adamis' participation in the White House Roundtable?
What financial strategies has Adamis employed recently?
What is the objective of Adamis' grant from the NIH?
How does Adamis plan to enhance its product portfolio?
